Jan Peter Mattsson
Founder chez ALBIREO PHARMA, INC.
Profil
Jan Peter Mattsson was the founder of Albireo Ltd.
(founded in 2008) where he held the title of Director, Chief Executive & Operating Officer from 2008 to 2015.
He is also the founder of Albireo AB (founded in 2008) where he currently holds the title of Chief Operating Officer since 2010.
Additionally, he is the founder of Albireo Pharma, Inc. (founded in 2003) where he currently holds the title of Chief Scientific Officer since 2023.
Dr. Mattsson's current job(s) include being a Director at Toleranzia AB since 2020 and a Director at Elobix AB since 2013.
Dr. Mattsson's former job(s) include being an Associate Director at AstraZeneca AB.
Dr. Mattsson's education history includes undergraduate and doctorate degrees from the University of Gothenburg.
Postes actifs de Jan Peter Mattsson
| Sociétés | Poste | Début |
|---|---|---|
| ALBIREO PHARMA, INC. | Founder | 08/12/2003 |
| TOLERANZIA AB | Director/Board Member | 01/01/2020 |
Albireo AB
 Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Founder | 01/02/2008 |
Elobix AB
 Elobix AB Miscellaneous Commercial ServicesCommercial Services Part of Ipsen SA, Elobix AB is a Swedish company that provides commercial physical research services. The private company is based in Gothenburg, Sweden. | Director/Board Member | 01/11/2013 |
Anciens postes connus de Jan Peter Mattsson
| Sociétés | Poste | Fin |
|---|---|---|
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Chief Executive Officer | 01/07/2015 |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Corporate Officer/Principal | - |
Formation de Jan Peter Mattsson
| University of Gothenburg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TOLERANZIA AB | Health Technology |
| Entreprise privées | 5 |
|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Health Technology |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
Elobix AB
Elobix AB Miscellaneous Commercial ServicesCommercial Services Part of Ipsen SA, Elobix AB is a Swedish company that provides commercial physical research services. The private company is based in Gothenburg, Sweden. | Commercial Services |
